Liver cirrhosis

The rise in hepatocellular carcinoma (HCC) mortality rates has caused researchers to focus increased attention on liver cirrhosis, a pathological condition known to lead to HCC. If hepatic fibrosis can be controlled, it follows that the risk of HCC among patients with chronic hepatitis can be reduced. In the quest for greater understanding of liver cirrhosis, the 1999 Yamaguchi Symposium on Liver Diseases brought together leading researchers in the field. Guest speakers included Michael J.P. Arthur, on mechanisms of the progression and regression of liver fibrosis; Mark A. Zern, on novel therapeutic modalities for hepatic disease; and Jiro Fujimoto, on gene therapy to inhibit progression to liver cirrhosis. The presentations by these groundbreaking scientists are collected in this volume along with those of other leading researchers in the field of hepatology, creating a valuable source for professionals concerned with hepatic fibrogenesis and hepatocarcinogenesis.

1. Mechanisms of Progression and Regression of Liver Fibrosis -- 2. Analysis of Proteins and Genes Dominantly Expressed in Stellate Cells of Activated Phenotype: the Molecular Approach to Liver Fibrosis -- 3. Novel Therapeutic Modalities for Hepatic Disease -- 4. Gene Therapy for Liver Cirrhosis: Novel Treatment in the New Millennium -- 5. Present Status and Future of Gene Therapy for Hepatic Fibrosis -- 6. Inhibitory Effects of the Herbal Medicine Sho-Saiko-To on Liver Fibrosis -- 7. Resolution of Fibrosis in Hepatitis C Patients with Sustained Response to Interferon: Long-Term Effects of Interferon Therapy on Histological Improvement -- 8. Factors Related to the Development of Hapatocelullar Carcinoma from Chronic Liver Diseases Type B and C -- 9. Quasispecies of Hepatitis C Virus in Serum and Liver in Three Different Parts of the Liver of Patients with Chronic Hepatitis -- 10. Development of Hepatocellular Carcinoma in Liver Cirrhosis: Pathomorphologic Viewpoint -- 11. Expression of HGF Activator (HGFA) and HGF Activator Inhibitor (HAI)-1 in Hepatocellular Carcinoma (HCC) -- 12. Significance of 1-6 Fucosylation in Hapatocellular Carcinoma -- 13. Energy Metabolism in Liver Cirrh…